ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
September 05, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives orphan drug designation from the FDA and EMA, representing the third candidate in the company’s ophthalmology pipeline and the...
ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
August 28, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR appoints three new members to the Company’s Scientific Advisory Board: Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong, who bring a tremendous amount of experience in the...
ProQR Announces Results for the Second Quarter of 2017
August 16, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key updates Data from two clinical trials of QR-010 presented at the European Cystic Fibrosis Conference. Enrollment completed in the Phase 1b clinical trial in cystic fibrosis (CF) and top-line...
ProQR Announces R&D Day in New York on June 15
May 09, 2017 07:00 ET
|
ProQR Therapeutics
Key updates: ProQR to host an R&D day in New York on June 15 from 8:00am to 1:00pm ETPresentations on development programs: QR-010 for cystic fibrosis, QR-110 for Leber’s congenital amaurosis...
ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
May 01, 2017 07:00 ET
|
ProQR Therapeutics
Key updates At ARVO ProQR will present additional positive pre-clinical proof-of-concept (PoC) data for QR-110 targeting LCA 10. The company has recently received IND clearance to start clinical...
ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
April 27, 2017 07:00 ET
|
ProQR Therapeutics
Key updates With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber’s...
ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
April 03, 2017 07:00 ET
|
ProQR Therapeutics
Key Updates ProQR received notice of grant for 2 key patents protecting QR-010 for CF in the US and EU until at least July 2033QR-010 is currently being studied in 64 homozygous F508del patients in a...
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
March 27, 2017 07:00 ET
|
ProQR Therapeutics
LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr....
ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
February 28, 2017 07:00 ET
|
ProQR Therapeutics
Key updates Major progress in the QR-010 development program for CF with presentation of positive clinical data at North American CF conference in October 2016On track to report data from the ongoing...
On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
February 27, 2017 07:00 ET
|
ProQR Therapeutics
LEIDEN, the Netherlands, Feb. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...